Free tool
Rare disease stocks
We cover 77 companies grouped under the Rare disease theme. The median market value in the group is $485.84M. Across the group, the median move over the past trading day is +2.39%. 62% of the 73 with a 200-day average trade above it. Price change over the past year runs from −38.5% to +307.7% across the middle 80 percent of the group, with a median of +42.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
77 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $33.90 | −8.30% | +24.72% | −9.02% |
| SEPN | Septerna, Inc. | $41.30 | +23.32% | +47.61% | +245.32% |
| ETON | Eton Pharmaceuticals, Inc. | $63.05 | +49.02% | +287.76% | +268.93% |
| ANIP | ANI Pharmaceuticals, Inc. | $75.65 | −3.47% | −3.54% | −16.24% |
| ANAB | AnaptysBio, Inc. | $58.37 | +8.88% | +94.78% | +335.60% |
| AVLN | Avalyn Pharma Inc. | $38.20 | +38.31% | +29.54% | +29.54% |
| MAZE | Maze Therapeutics, Inc. | $30.42 | +6.03% | −23.51% | +128.55% |
| FBRX | Forte Biosciences, Inc. | $76.97 | +0.61% | +226.01% | +580.25% |
| TRAX | First Tracks Biotherapeutics, Inc. | $45.11 | +7.33% | +137.42% | +137.42% |
| XERS | Xeris Biopharma Holdings, Inc. | $8.74 | +6.46% | +18.91% | +12.48% |
| TYRA | Tyra Biosciences, Inc. | $26.69 | −14.07% | −0.37% | +122.42% |
| KALV | KalVista Pharmaceuticals Inc | $27.00 | 0.00% | +74.64% | +107.85% |
| OMER | Omeros Corporation | $19.28 | +70.02% | +17.70% | +343.22% |
| JBIO | Jade Biosciences, Inc. | $21.84 | +9.47% | +54.24% | +176.46% |
| MLTX | MoonLake Immunotherapeutics | $15.56 | −21.73% | +30.21% | −71.52% |
| SVRA | Savara Inc. | $5.60 | +3.13% | −0.71% | +78.34% |
| AVTX | Avalo Therapeutics, Inc. | $19.74 | +1.23% | +15.98% | +110.00% |
| WVE | Wave Life Sciences, Inc. | $5.25 | −11.32% | −67.08% | −47.18% |
| CLYM | Climb Bio Inc | $17.84 | +39.48% | +375.73% | +619.35% |
| DSGN | Design Therapeutics, Inc. | $15.68 | +31.99% | +72.31% | +201.54% |
| ANNX | Annexon, Inc. | $5.15 | +0.39% | +9.81% | +139.53% |
| DBVT | DBV Technologies S.A. | $14.97 | +7.70% | −21.42% | +52.91% |
| SLN | Silence Therapeutics plc | $13.67 | +13.26% | +122.28% | +170.16% |
| PHAR | Pharming Group N.V. | $11.46 | −11.93% | −33.14% | −19.75% |
| STTK | Shattuck Labs, Inc. | $8.06 | +14.49% | +117.25% | +710.87% |
| TECX | Tectonic Therapeutic, Inc. | $37.71 | +23.20% | +80.34% | +53.48% |
| IRWD | Ironwood Pharmaceuticals, Inc. | $4.39 | +12.28% | +2.81% | +245.67% |
| ASMB | Assembly Biosciences, Inc. | $35.33 | +36.36% | +4.68% | +32.72% |
| ZVRA | Zevra Therapeutics, Inc. | $12.04 | +24.00% | +44.36% | +28.63% |
| AGMB | AgomAb Therapeutics NV | $14.02 | +12.07% | −4.30% | −4.30% |
| GYRE | Gyre Therapeutics, Inc. | $6.68 | +8.97% | −1.91% | −18.54% |
| CRMD | CorMedix Inc. | $8.56 | +12.63% | −29.61% | −37.65% |
| VALN | Valneva SE | $6.78 | +36.69% | −24.29% | −28.10% |
| ZURA | Zura Bio Limited | $6.32 | +17.47% | +13.87% | +208.29% |
| AQST | Aquestive Therapeutics, Inc. | $5.08 | +36.19% | −21.24% | +31.61% |
| SPRY | ARS Pharmaceuticals, Inc. | $5.72 | −0.69% | −50.22% | −57.66% |
| KMDA | Kamada Ltd. Ordinary Shares | $8.63 | +23.46% | +26.48% | +26.12% |
| EPRX | Eupraxia Pharmaceuticals Inc. | $7.42 | +20.26% | −1.98% | +41.87% |
| QTTB | Q32 Bio Inc. | $16.32 | +7.30% | +374.42% | +728.43% |
| RZLT | Rezolute, Inc. | $5.01 | +1.42% | +131.41% | −28.43% |
| AVIR | Atea Pharmaceuticals, Inc. | $5.43 | +12.66% | +56.03% | +48.36% |
| LRMR | Larimar Therapeutics, Inc. | $4.16 | +8.62% | +19.88% | +11.83% |
| XFOR | X4 Pharmaceuticals, Inc. | $4.16 | +5.58% | +6.94% | +4.79% |
| ENTA | Enanta Pharmaceuticals, Inc. | $14.08 | +10.60% | −2.36% | +62.59% |
| UPB | Upstream Bio, Inc. | $7.18 | +12.19% | −73.48% | −57.08% |
| IKT | Inhibikase Therapeutics, Inc. | $2.50 | +6.38% | +28.21% | +42.05% |
| PRQR | ProQR Therapeutics N.V. | $2.38 | +37.57% | +19.60% | +5.78% |
| IFRX | InflaRx N.V. | $2.46 | +44.71% | +125.69% | +167.10% |
| TRDA | Entrada Therapeutics, Inc. | $7.62 | +25.33% | −24.18% | +35.35% |
| TTRX | Turn Therapeutics Inc. | $9.73 | +25.06% | +107.46% | +39.00% |
| FULC | Fulcrum Therapeutics, Inc. | $3.86 | +3.49% | −64.65% | −39.78% |
| SION | Sionna Therapeutics, Inc. | $6.25 | −86.23% | −84.06% | −74.02% |
| ELDN | Eledon Pharmaceuticals, Inc. | $3.47 | −2.80% | +114.20% | +35.02% |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $4.45 | +30.12% | −25.83% | +185.26% |
| IVVD | Invivyd, Inc. | $0.94 | +53.89% | −62.45% | +67.62% |
| AKBA | Akebia Therapeutics, Inc. | $0.96 | −25.12% | −38.17% | −68.37% |
| SLGL | Sol-Gel Technologies Ltd. | $81.72 | +2.37% | +93.88% | +289.14% |
| RNA | Prosensa Holding B.V. Ordinary Shares | $14.00 | +21.00% | −5.08% | −5.08% |
| PEPG | PepGen Inc. | $3.43 | +80.26% | −52.23% | +161.45% |
| CRDL | Cardiol Therapeutics Inc. | $2.00 | +73.16% | +101.21% | +75.44% |
| KROS | Keros Therapeutics, Inc. | $11.68 | +14.40% | −37.00% | −20.87% |
| ANTX | AN2 Therapeutics, Inc. | $5.66 | +14.81% | +409.91% | +403.11% |
| SIGA | SIGA Technologies, Inc. | $3.04 | −1.94% | −45.19% | −60.50% |
| ARMP | Armata Pharmaceuticals, Inc. | $5.56 | +7.96% | −15.24% | +113.85% |
| MSLE | Satellos Bioscience Inc. | $9.40 | −0.58% | +51.52% | +82.17% |
| PLX | Protalix BioTherapeutics, Inc. | $2.41 | +0.42% | +38.51% | +50.62% |
| SPRB | Spruce Biosciences, Inc. | $63.40 | +50.99% | −30.10% | +697.48% |
| MDWD | MediWound Ltd. | $12.97 | −10.24% | −29.59% | −24.81% |
| AARD | Aardvark Therapeutics, Inc. | $7.25 | +8.37% | −45.03% | −19.80% |
| UNCY | Unicycive Therapeutics, Inc. | $5.47 | +6.63% | −5.69% | +27.51% |
| MIST | Milestone Pharmaceuticals Inc. | $1.16 | +2.65% | −43.41% | −31.36% |
| EQ | Equillium, Inc. | $2.18 | −11.38% | +42.48% | +14.74% |
| CPIX | Cumberland Pharmaceuticals Inc. | $8.70 | +59.59% | +118.59% | +166.87% |
| INO | Inovio Pharmaceuticals, Inc. | $1.29 | +32.99% | −23.67% | −33.85% |
| RFL | Rafael Holdings, Inc. | $2.24 | −1.75% | +77.78% | +52.38% |
| PTHS | Pelthos Therapeutics Inc. | $27.20 | −1.41% | −7.64% | +20.41% |
| PYPD | PolyPid Ltd. | $5.10 | +28.14% | +17.24% | +47.83% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.